Bulgaria vs China: Average cost of multi drug-resistant tuberculosis treatment
Bulgaria
6,271 constant 2022 US$
in 2024
China
20,028 constant 2022 US$
in 2024
Bulgaria rank
6th
China rank
4th
Average cost of multi drug-resistant tuberculosis treatment over time
- Bulgaria
- China
How they compare
China currently reports 20,028 constant 2022 US$ against 6,271 constant 2022 US$ in Bulgaria, a difference of 13,757 constant 2022 US$.
That makes China's figure about 3.2 times Bulgaria's.
Across all 7 years both countries report, China has been ahead every year.
Bulgaria ranks 6th and China ranks 4th of 92 countries.
China has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bulgaria | China | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,490 constant 2022 US$ | 7,884 constant 2022 US$ | 5,394 constant 2022 US$ | China |
| 2020s | 4,840 constant 2022 US$ | 20,415 constant 2022 US$ | 15,575 constant 2022 US$ | China |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Bulgaria or China?
- China, at 20,028 constant 2022 US$ against 6,271 constant 2022 US$ in Bulgaria as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Bulgaria and China?
- 13,757 constant 2022 US$, with China ahead.
- How many years of comparable data are there for Bulgaria and China?
- 7 years are reported by both, from 2018 to 2024.
- How do Bulgaria and China rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Bulgaria ranks 6th and China ranks 4th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.